Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2008 3
2010 1
2011 5
2012 1
2013 2
2014 1
2015 5
2016 1
2017 2
2019 2
2021 1
2022 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.
Audrain M, Egesipe AL, Tentillier N, Font L, Ratnam M, Mottier L, Clavel M, Le Roux-Bourdieu M, Fenyi A, Ollier R, Chevalier E, Guilhot F, Fuchs A, Piorkowska K, Carlyle B, Arnold SE, Berry JD, Luthi-Carter R, Adolfsson O, Pfeifer A, Kosco-Vilbois M, Seredenina T, Afroz T. Audrain M, et al. Among authors: seredenina t. Brain Commun. 2023 Nov 3;5(6):fcad306. doi: 10.1093/braincomms/fcad306. eCollection 2023. Brain Commun. 2023. PMID: 38025276 Free PMC article.
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework.
Ollier R, Fuchs A, Gauye F, Piorkowska K, Menant S, Ratnam M, Montanari P, Guilhot F, Phillipe D, Audrain M, Egesipe AL, Névoltris D, Seredenina T, Pfeifer A, Kosco-Vilbois M, Afroz T. Ollier R, et al. Among authors: seredenina t. MAbs. 2023 Jan-Dec;15(1):2232087. doi: 10.1080/19420862.2023.2232087. MAbs. 2023. PMID: 37408314 Free PMC article.
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
Afroz T, Chevalier E, Audrain M, Dumayne C, Ziehm T, Moser R, Egesipe AL, Mottier L, Ratnam M, Neumann M, Havas D, Ollier R, Piorkowska K, Chauhan M, Silva AB, Thapa S, Stöhr J, Bavdek A, Eligert V, Adolfsson O, Nelson PT, Porta S, Lee VM, Pfeifer A, Kosco-Vilbois M, Seredenina T. Afroz T, et al. Among authors: seredenina t. Neurobiol Dis. 2023 Apr;179:106050. doi: 10.1016/j.nbd.2023.106050. Epub 2023 Feb 20. Neurobiol Dis. 2023. PMID: 36809847 Free article.
NADPH oxidase 4 is dispensable for skin myofibroblast differentiation and wound healing.
Siedlar AM, Seredenina T, Faivre A, Cambet Y, Stasia MJ, André-Lévigne D, Bochaton-Piallat ML, Pittet-Cuénod B, de Seigneux S, Krause KH, Modarressi A, Jaquet V. Siedlar AM, et al. Among authors: seredenina t. Redox Biol. 2023 Apr;60:102609. doi: 10.1016/j.redox.2023.102609. Epub 2023 Jan 13. Redox Biol. 2023. PMID: 36708644 Free PMC article.
Pharmacological characterization of the seven human NOX isoforms and their inhibitors.
Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, Mahiout Z, Jansen-Dürr P, Knaus UG, Doroshow J, Stocker R, Krause KH, Jaquet V. Augsburger F, et al. Among authors: seredenina t. Redox Biol. 2019 Sep;26:101272. doi: 10.1016/j.redox.2019.101272. Epub 2019 Jul 11. Redox Biol. 2019. PMID: 31330481 Free PMC article.
NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?
Sorce S, Stocker R, Seredenina T, Holmdahl R, Aguzzi A, Chio A, Depaulis A, Heitz F, Olofsson P, Olsson T, Duveau V, Sanoudou D, Skosgater S, Vlahou A, Wasquel D, Krause KH, Jaquet V. Sorce S, et al. Among authors: seredenina t. Free Radic Biol Med. 2017 Nov;112:387-396. doi: 10.1016/j.freeradbiomed.2017.08.006. Epub 2017 Aug 12. Free Radic Biol Med. 2017. PMID: 28811143 Free article. Review.
30 results